LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 913 | 5418 | 0.1686 | -0.6092 |
| SK-BR-3 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 2543 | 697 | 5418 | 0.1286 | -0.6947 |
| SK-BR-3 | AZD7762 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 2030 | 5418 | 0.3747 | -0.1872 |
| SK-BR-3 | AZD7762 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 1690 | 5418 | 0.3120 | -0.3129 |
| SK-BR-3 | AZD7762 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 1559 | 5418 | 0.2877 | -0.3621 |
| SK-BR-3 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1345 | 5418 | 0.2480 | -0.4431 |
| SK-BR-3 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1307 | 5418 | 0.2414 | -0.4570 |
| SK-BR-3 | AZD7762 | 10 | uM | LJP6 | 72 | hr | 2543 | 1226 | 5418 | 0.2264 | -0.4880 |
| SK-BR-3 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 2543 | 2013 | 5418 | 0.3717 | -0.1933 |
| SK-BR-3 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 1763 | 5418 | 0.3254 | -0.2859 |
| SK-BR-3 | AZD8055 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 1782 | 5418 | 0.3289 | -0.2789 |
| SK-BR-3 | AZD8055 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1906 | 5418 | 0.3518 | -0.2329 |
| SK-BR-3 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 2543 | 1791 | 5418 | 0.3303 | -0.2762 |
| SK-BR-3 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 2543 | 1586 | 5418 | 0.2925 | -0.3523 |
| SK-BR-3 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 2543 | 5284 | 5418 | 0.9764 | 0.9589 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5536 | 5418 | 1.0222 | 1.0417 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5574 | 5418 | 1.0293 | 1.0551 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 5746 | 5418 | 1.0607 | 1.1117 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 2543 | 5732 | 5418 | 1.0582 | 1.1072 |
| SK-BR-3 | Sorafenib | 10 | uM | LJP6 | 72 | hr | 2543 | 2495 | 5418 | 0.4622 | -0.0144 |
| SK-BR-3 | CP466722 | 0.04 | uM | LJP5 | 72 | hr | 2543 | 6180 | 5752 | 1.0744 | 1.1255 |
| SK-BR-3 | CP466722 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5836 | 5752 | 1.0148 | 1.0248 |
| SK-BR-3 | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5746 | 5752 | 0.9990 | 0.9980 |
| SK-BR-3 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 5881 | 5752 | 1.0225 | 1.0381 |
| SK-BR-3 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 2543 | 5979 | 5752 | 1.0394 | 1.0665 |